Abstract
The use of placebo in clinical trials has been repeatedly challenged as being unacceptable from an ethical point of view. The present paper responds to this criticism by taking up the issue in the light of the pertinent provisions of the Helsinki Declaration. Examples from different therapeutic areas are given that highlight the importance of placebo in situations in which its use is acceptable according to the Declaration. Particular emphasis is given to the question of active control trials, which, under conditions of low assay sensitivity, may become an ethically less acceptable approach than the use of a placebo control.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Rothman KJ and Michels, KB (1994) The continuing unethical use of placebo controls, New England Journal of Medicine 331: 394–398.
World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Available at: http://www.wma.net/e/policy
Vastag B (2000) Helsinki discord? A controversial declaration, Journal of the American Medical Association 284: 2983–2985
Forster HP, Emanuel E and Grady C (2001) The 2000 revision of the Declaration of Helsinki: a step forward or more confusion?, Lancet 358: 1449–1453.
Echt DS., Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L and Greene HL (1991) Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiae Arrhythmia Suppression Trial, New England Journal of Medicine 324: 781–788.
McCloskey RV, Straube RC, Sanders C, Smith SM and Smith CR (1994) Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group, Annals of Internal Medicine 121: 1–5.
Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, Wilding G, Sears K, Culkin DJ, Thompson IM Jr, Bueschen AJ and Lowe BA (1998) Bilateral orchiectomy with or without flutamide for metastatic prostate cancer, New England Journal of Medicine 339: 1036–1042.
European Agency for the Evaluation of Medicinal Products. European Public Assessment Report (EPAR) on Azomyr (desloratadine). Available at: http://www.emea.eu.int.
Schoenen J and Sawyer J (1997) Zolmitriptan (Zomig, 311C90), a novel dual central and peripheral 5HT1B/1D agonist: an overview of efficacy, Cephalagia 17 (Suppl. 18): 28–40.
Leber PD (1989) Hazards of inference: the active control investigation, Epilepsia 30 Suppl. 1: S57-S63.
Emanuel EJ and Miiler FG (2001) The ethics of placebo-controlled trials — a middle ground, New England Journal of Medicine 345: 915–919.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Singer, E.A. The necessity and the value of placebo. SCI ENG ETHICS 10, 51–56 (2004). https://doi.org/10.1007/s11948-004-0062-0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s11948-004-0062-0